← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Dxdiscovery, Inc.
Reno, NV
$10,094,377
Total funding
9
Grants
Funding over time
peak $1.5M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,094,377 · 9
By mechanism
R44$5,527,964 · 2
R43$1,605,652 · 3
N01$1,469,691 · 1
R41$1,191,671 · 2
N43$299,399 · 1
Investigators at Dxdiscovery, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Rapid immunoassay for diagnosis of coccidioidomycosis$1,469,691
N01 · FY2022 · AI
Point-of-care lateral flow immunoassay for diagnosis of pertussis$1,009,408
R44 · FY2023 · AI
Point-of-care lateral flow immunoassay for diagnosis of pertussis$999,716
R44 · FY2024 · AI
Point-of-care lateral flow immunoassay for diagnosis of pertussis$989,461
R44 · FY2025 · AI
Lateral flow immunoassay for rapid diagnosis of tinea capitis and onychomycosis$893,413
R44 · FY2020 · EB
Lateral flow immunoassay for rapid diagnosis of tinea capitis and onychomycosis$588,922
R44 · FY2019 · EB
Point-of-care immunoassay for early diagnosis of pertussis$406,540
R44 · FY2016 · AI
Point-of-care immunoassay for early diagnosis of pertussis$351,332
R44 · FY2017 · AI
Biomarker discovery for immunodiagnosis of invasive candidiasis$300,000
R41 · FY2013 · AI
Biomarker discovery for immunodiagnosis of invasive candidiasis$300,000
R41 · FY2014 · AI
A Diagnostic for Coccidioidomycosis$299,399
N43 · FY2020 · AI
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum$298,958
R41 · FY2014 · AI
Immunoassay for early diagnosis of mucormycosis$298,013
R43 · FY2020 · AI
Point-of-care immunoassay for early diagnosis of pertussis$297,775
R43 · FY2015 · AI
Immunoassay for early diagnosis of mucormycosis$297,133
R43 · FY2019 · AI
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum$292,713
R41 · FY2015 · AI
Point-of-care immunoassay for early diagnosis of pertussis$292,091
R43 · FY2014 · AI
Point-of-care immunoassay for early diagnosis of pertussis$289,172
R44 · FY2018 · AI
Point of care immunoassay for rapid diagnosis of tinea capitis$199,920
R43 · FY2016 · EB
Point of care immunoassay for rapid diagnosis of tinea capitis$189,220
R43 · FY2017 · EB